AlloVir Gains PRIME Status For Anti-Virus T-Cell Therapy

Led By Ex-Alexion CEO David Hallal

Joining the ElevateBio stable last May, the company has now gained priority status in the US and Europe for its novel therapy for viral infections in stem cell transplant patients.

EMA_Amsterdam
The European Medicines Agency, now located in Amsterdam • Source: EMA

Cell therapy specialist AlloVir Inc. has gained a valuable PRIME status in Europe for its lead candidate, a novel T-cell therapy to treat viral infections in stem cell transplant patients.

The Houston, Texas-headquartered company is headed up by one-time Alexion Pharmaceuticals Inc. CEO David Hallal, who is also co-founder...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category